Current status of head and neck sarcomas in Japan in 2016–2019: an analysis using the national cancer registry
International Journal of Clinical Oncology · 2024
DOI: 10.1007/s10147-024-02484-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2024. Verfasst von Ryoko Rikitake und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Health Policy, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan. …. Hauptthemen laut MEDLINE: Registries, Head and Neck Neoplasms, Sarcoma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Cancer Center Research and Development Fund, The University of Tokyo.
Abstract (Originalsprache)
Background
Head and neck sarcomas are especially rare in Asia, leading to limited clinical evidence. This study aimed to investigate the incidence, clinical features, treatment status, and outcome of these sarcomas using data from the National Cancer Registry in Japan.
Methods
All head and neck sarcomas diagnosed between 2016 and 2019 and recorded in the National Cancer Registry were analyzed. Data on sex, age, primary site, histological type, stage, treatment modality, and prognostic information were collected. Age-adjusted incidence and 3-year survival rates of patients with head and neck sarcomas were calculated.
Results
Overall, 635 head and neck sarcoma patients were identified. Head and neck sarcoma occurred more frequently in men and patients in their 70 s. The age-adjusted annual incidence rate was 0.125 per 100,000 patients in the 2015 Japanese model or 0.089 per 100,000 patients in the world population model. The nasal cavity and paranasal sinuses were the most frequent primary sites, with rhabdomyosarcoma as the most common histologic type. Treatment typically involved chemotherapy and/or radiation therapy for rhabdomyosarcoma and Ewing’s sarcoma, whereas surgical approaches for other types. Three-year survival rate of head and neck sarcoma patients was 64.8%.
Conclusions
Head and neck sarcomas occurred rarely, but most frequently in the nasal cavity and paranasal sinuses in Japan. Poor outcomes were observed for sarcoma patients than for non-sarcoma head and neck cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Public Health and Health Policy, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-0033, Japan. rikitake@m.u-tokyo.ac.jp.
- Institute for Cancer Control, Division of Health Services Research, National Cancer Center, Tokyo, Japan. rikitake@m.u-tokyo.ac.jp.
- Rare Cancer Center, National Cancer Center, Tokyo, Japan. rikitake@m.u-tokyo.ac.jp.
- Institute for Cancer Control, Division of Health Services Research, National Cancer Center, Tokyo, Japan.
- Rare Cancer Center, National Cancer Center, Tokyo, Japan.
- Department of Head and Neck Oncology, National Cancer Center Hospital, Tokyo, Japan.
Förderung
- National Cancer Center Research and Development Fund
- The University of Tokyo
Zitieren
APA
Rikitake, R., Mizushima, Y., Yoshimoto, S., Higashi, T., Satake, T., Morizane, C., & Kawai, A. (2024). Current status of head and neck sarcomas in Japan in 2016–2019: an analysis using the national cancer registry. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-024-02484-5
Vancouver
Rikitake R, Mizushima Y, Yoshimoto S, Higashi T, Satake T, Morizane C, et al. Current status of head and neck sarcomas in Japan in 2016–2019: an analysis using the national cancer registry. International Journal of Clinical Oncology. 2024. doi:10.1007/s10147-024-02484-5
BibTeX
@article{Rikitake2024,
author = {Rikitake, Ryoko and Mizushima, Yu and Yoshimoto, Seiichi and Higashi, Takahiro and Satake, Tomoyuki and Morizane, Chigusa and Kawai, Akira},
title = {Current status of head and neck sarcomas in Japan in 2016–2019: an analysis using the national cancer registry},
journal = {International Journal of Clinical Oncology},
year = {2024},
doi = {10.1007/s10147-024-02484-5}
}
EUVIMED